Claims
- 1. A compound selected from those of formula (I): ##STR39## in which: Z represents oxygen or sulfur,
- R.sub.1 represents hydrogen or (C.sub.1 -C.sub.6) alkyl,
- R.sub.2 represents hydrogen or (C.sub.1 -C.sub.6) alkyl,
- n is an integer of 1 to 6 inclusive,
- R.sub.3 represents an amino group substituted with:
- an phenylsulfonyl optionally substituted with alkyl, alkoxy, hydroxyl, or halogen,
- its enantiomers, diastereoisomers and epimers and its pharmaceutically-acceptable acid addition salts.
- 2. A compound as claimed in claim 1, wherein R.sub.1 is a methyl group.
- 3. A compound as claimed in claim 1, wherein R.sub.2 is an n-propyl group.
- 4. A compound as claimed in claim 1, wherein R.sub.1 is in the 5-position.
- 5. A compound as claimed in claim 1, wherein R.sub.2 is a hydrogen atom.
- 6. A compound as claimed in claim 1, selected from 5-methoxy-3-{N-propyl-N-[2-(4-toluenesulfonylamino)ethyl]amino}chroman, its isomers and its addition salts with a pharmaceutically-acceptable acid.
- 7. A compound as claimed in claim 1, selected from 5-methoxy-(+)-3-{N-propyl-N-[2-(4-toluenesulfonylamino)ethyl]amino}chroman, and its addition salts with a pharmaceutically-acceptable acid.
- 8. A compound as claimed in claim 1, selected from 5-methoxy-(-)-3-{N-propyl-N-[2-(4-toluenesulfonylamino)ethyl]amino}chroman, and its addition salts with a pharmaceutically-acceptable acid.
- 9. A compound as claimed in claim 1, selected from 5-methoxy-3-{N-n-propyl-N-[4-(4-toluenesulfonylamino)butyl]amino}chroman, its isomers and its addition salts with a pharmaceutically-acceptable acid.
- 10. A compound as claimed in claim 1, selected from 5-methoxy-(+)-3-{N-n-propyl-N-[4-(4-toluenesulfonylamino)butyl]amino}chroman, and its addition salts with a pharmaceutically-acceptable acid.
- 11. A compound as claimed in claim 1, selected from 5-methoxy-(-)-3-{N-n-propyl-N-[4-(4-toluenesulfonylamino)butyl]amino}chroman, and its addition salts with a pharmaceutically-acceptable acid.
- 12. A pharmaceutical composition comprising the active principle as claimed in claim 1, which is useful in the treatment of depression, stress, psychoses, anxiety, pain, schizophrenia, hypertension, or atheroma, and as an agent modifying feeding and sexual behavior, together with a pharmaceutically-acceptable diluent.
- 13. A method for treating a living animal afflicted with a disorder of the serotoninergic system comprising the step of administering to the said living animal an amount of a compound of claim 1 which is suitable for the alleviation of said condition.
Priority Claims (1)
Number |
Date |
Country |
Kind |
90 04481 |
Apr 1990 |
FRX |
|
Parent Case Info
The present invention is a division of our prior-filed copending U.S. application Ser. No. 07/959,044, filed Oct. 9, 1992, in turn a division of Ser. No. 07/677,136, filed Mar. 29, 1991, now U.S. Pat. No. 5,252,578.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5049564 |
BeBernardis et al. |
Sep 1991 |
|
5075303 |
Cliffe |
Dec 1991 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
222996 |
Apr 1977 |
EPX |
279150 |
Mar 1979 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Korobov, et al., Chem. Phys. Lett., 45 (1977), p. 498. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
959044 |
Oct 1992 |
|
Parent |
677136 |
Mar 1991 |
|